Metformin and long non-coding RNAs in breast cancer.
J Transl Med
; 21(1): 155, 2023 02 27.
Article
in En
| MEDLINE
| ID: mdl-36849958
ABSTRACT
Breast cancer (BC) is the second most common cancer and cause of death in women. In recent years many studies investigated the association of long non-coding RNAs (lncRNAs), as novel genetic factors, on BC risk, survival, clinical and pathological features. Recent studies also investigated the roles of metformin treatment as the firstline treatment for type 2 diabetes (T2D) played in lncRNAs expression/regulation or BC incidence, outcome, mortality and survival, separately. This comprehensive study aimed to review lncRNAs associated with BC features and identify metformin-regulated lncRNAs and their mechanisms of action on BC or other types of cancers. Finally, metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, by several molecular mechanisms have been described in this review. In addition, metformin action on other types of cancers by regulating ten lncRNAs including AC006160.1, Loc100506691, lncRNA-AF085935, SNHG7, HULC, UCA1, H19, MALAT1, AFAP1-AS1, AC026904.1 is described.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Diabetes Mellitus, Type 2
/
RNA, Long Noncoding
/
Metformin
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
J Transl Med
Year:
2023
Document type:
Article
Affiliation country:
Iran